中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (12): 2760-2772.doi: 10.4103/NRR.NRR-D-23-01490

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

烟酰胺腺嘌呤二核苷酸对神经行为表型的影响:可改善新生儿缺氧缺血性脑损伤

  

  • 出版日期:2024-12-15 发布日期:2024-03-30
  • 基金资助:
    国家自然科学基金;江苏省自然科学基金项目

Nicotinamide adenine dinucleotide treatment confers resistance to neonatal ischemia and hypoxia: effects on neurobehavioral phenotypes

Xiaowen Xu1, #, Xinxin Wang1, #, Li Zhang1, #, Yiming Jin1, Lili Li1, Meifang Jin1, Lianyong Li2, Hong Ni1, *   

  1. 1Division of Brain Science, Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, Jiangsu Province, China; 2Department of Pediatric Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
  • Online:2024-12-15 Published:2024-03-30
  • Contact: Hong Ni, PhD, nhdoctor@163.com.
  • Supported by:
    This study was supported by the National Natural Science Foundation of China, Nos. 81871024 (to HN), 82301957 (to XW), 82001382 (to LL), 62127810 (to HN); the Natural Science Foundation of Jiangsu Province of China, No. SBK2020040785 (to LL).

摘要:

新生儿缺氧缺血性脑损伤是导致缺氧缺血性脑病和脑瘫的主要原因。目前临床上治疗缺氧性脑损伤的有效方法仍然很少。烟酰胺腺嘌呤二核苷酸在抗缺氧性脑损伤方面具有一定的神经保护作用,但其作用机制尚等进一步探讨。为了解外源性烟酰胺腺嘌呤二核苷酸对新生缺氧缺血性脑损伤小鼠模型的神经保护作用及其分子机制。实验于手术前 30 min腹腔注射烟酰胺腺嘌呤二核苷酸(5mg/kg),之后每 24 h注射1次。结果显示,烟酰胺腺嘌呤二核苷酸可以缩小缺氧缺血脑损伤小鼠的大脑梗死面积,改善小鼠认知行为学表现。TMT 蛋白质组学检测显示,烟酰胺腺嘌呤二核苷酸干预后的缺氧缺血性脑损伤小鼠多种蛋白质发生了变化。PRM平行反应监测和 Western 印迹进一步证实了 SERPINA3N、FN1、NT5C1A、MAP2 和 CPLX2 等蛋白的表达。蛋白质组学结果表明,烟酰胺腺嘌呤二核苷酸可通过炎症相关的途径,包括核因子-kappa B 信号通路、丝裂原活化蛋白激酶信号通路和磷脂酰肌醇 3 激酶/蛋白激酶 B 信号通路改善缺氧缺血性脑损伤。这些研究结果表明,使用烟酰胺腺嘌呤二核苷酸治疗可通过炎症相关途径改善缺氧缺血性脑损伤小鼠的神经行为表型,提示烟酰胺腺嘌呤二核苷酸可能成为新生儿缺氧缺血脑损伤治疗的潜在药物。

https://orcid.org/0000-0002-5698-7284 (Hong Ni)

Abstract: Neonatal hypoxic-ischemic brain injury is the main cause of hypoxic-ischemic encephalopathy and cerebral palsy. Currently, there are few effective clinical treatments for neonatal hypoxic-ischemic brain injury. Here, we investigated the neuroprotective and molecular mechanisms of exogenous nicotinamide adenine dinucleotide, which can protect against hypoxic injury in adulthood, in a mouse model of neonatal hypoxic-ischemic brain injury. In this study, nicotinamide adenine dinucleotide (5 mg/kg) was intraperitoneally administered 30 minutes before surgery and every 24 hours thereafter. The results showed that nicotinamide adenine dinucleotide treatment improved body weight, brain structure, adenosine triphosphate levels, oxidative damage, neurobehavioral test outcomes, and seizure threshold in experimental mice. Tandem mass tag proteomics revealed that numerous proteins were altered after nicotinamide adenine dinucleotide treatment in hypoxic-ischemic brain injury mice. Parallel reaction monitoring and western blotting confirmed changes in the expression levels of proteins including serine (or cysteine) peptidase inhibitor, clade A, member 3N, fibronectin 1, 5′-nucleotidase, cytosolic IA, microtubule associated protein 2, and complexin 2. Proteomics analyses showed that nicotinamide adenine dinucleotide ameliorated hypoxic-ischemic injury through inflammation-related signaling pathways (e.g., nuclear factor-kappa B, mitogen-activated protein kinase, and phosphatidylinositol 3 kinase/protein kinase B). These findings suggest that nicotinamide adenine dinucleotide treatment can improve neurobehavioral phenotypes in hypoxic-ischemic brain injury mice through inflammation-related pathways.

Key words: brain injury, cerebral palsy, hypoxia, hypoxic-ischemic brain injury, inflammation, neuroprotection, nicotinamide adenine dinucleotide, neonate, nicotinamide adenine dinucleotide, proteomics